Semax subcutaneous vs. intranasal: what the evidence actually shows

What did @longevity.lori actually say?

She reported that three days into subcutaneous semax injections, she feels "butterflies in my stomach for no reason" and a significant lift in mood, specifically tied to what she describes as seasonal affective disorder that hits her every spring. She contrasted this favorably with a previous bad experience using intranasal semax, and attributed the effect to dopamine pathway activity. She stopped short of calling it a cure, framing it as "worth a try" for others feeling similarly.

That framing is actually more restrained than a lot of peptide content online. She's describing a personal experience, not making a clinical prescription. That context matters when evaluating what she got right and what she glossed over.

Does the science back this up?

Partly, yes. Semax has legitimate research behind it, mostly from Russian and Eastern European labs, which is a real limitation to keep in mind. The dopamine pathway claim isn't invented.

Semax is a synthetic analogue of ACTH(4-7), and it has shown activity on dopaminergic and serotonergic systems in animal studies. A 2009 paper by Levitskaya et al. in the journal Bulletin of Experimental Biology and Medicine documented semax's influence on monoamine neurotransmitter levels in rat brain tissue, including dopamine. Human data is much thinner. A 2007 clinical trial by Kaplan et al. published in Zhurnal Nevrologii i Psikhiatrii looked at semax in patients with cognitive decline and noted mood-adjacent benefits, but this is not a controlled study of subcutaneous administration in otherwise healthy adults with SAD.

The "butterflies" sensation she describes could plausibly be a physiological response to dopaminergic stimulation, or it could be a placebo effect amplified by expectation. Three days is not enough to disentangle those two things.

What did they get wrong (or right)?

She got the dopamine mechanism directionally correct, but overclaimed the certainty. Saying "of course it acts on dopamine pathways" makes a nuanced, mostly-animal-based finding sound like settled pharmacology. It is not.

The comparison between subcutaneous and intranasal routes is more interesting than she let on. Intranasal semax is the formulation with the most research behind it, full stop. The subcutaneous route bypasses nasal mucosal absorption and may produce different plasma kinetics, but there is no published head-to-head comparison of the two delivery methods in humans for mood outcomes. Her preference for sub-Q may be real, but it is not evidence-backed in the way she implies.

What she got right: she did not claim semax treats or cures SAD. She did not give a dose. She disclosed her personal history and acknowledged she might "sound crazy." For TikTok peptide content, that level of epistemic humility is genuinely above average. She also correctly identified that spring-pattern SAD is a real phenomenon, distinct from the more commonly discussed winter variant.

What should you actually know?

Semax is not FDA-approved for any indication in the United States. It is not available at licensed retail pharmacies. If you are obtaining it, you are likely purchasing it from a research chemical supplier or compounding pharmacy operating in a regulatory gray area. That matters for quality control, dosing accuracy, and sterility, especially with injectable formulations.

Spring-onset SAD is real. A 1991 paper by Wehr et al. in Archives of General Psychiatry established that a subset of seasonal mood disorder patients cycle in the spring rather than winter, often presenting with anxiety and agitation rather than the classic low-energy winter pattern. If that describes you, a telehealth provider can discuss evidence-based options including light therapy adjustment, SSRIs, and behavioral interventions before you reach for a peptide with limited human data.

The three-day timeline she describes is also too short to draw conclusions. Many peptides, stimulants, and even placebos produce noticeable early effects that attenuate over weeks. A three-day subjective report is a data point of one, not a treatment recommendation.